Harvard Bioscience Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $86.6M-8.0% YoYTTM through 31 Dec 2025
Net Income -$56.7MTTM through 31 Dec 2025
Free Cash Flow $5.5MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 57.7% |
| Net Margin | -65.5% |
Returns
-412.8%ROE
-70.8%ROA
Balance Sheet Health
Debt / Equity2.61x
Current Ratio2.20x
Net Debt$30.8M
Cash & Equivalents$86.1M
Quality Metrics
FCF Margin6.4%
Rule of 4010.0
Earnings-Beat Rate33.3%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Preclinical | $46.8M | ||
| Cellular and Molecular Technologies (CMT) | $39.8M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.